Divi’s Laboratories, an Indian pharmaceutical firm, encountered a 49.2% decline in its quarterly earnings, falling short of analysts’ predictions. This decline was primarily attributed to pricing challenges experienced in key markets, particularly the United States, where the company operates as a generic drug manufacturer.
During the first quarter ending on June 30, the company’s consolidated profit amounted to 356 crore rupees, a notable decrease compared to the 702 crore rupees recorded in the same period the previous year. Based in Hyderabad, Divi’s Laboratories specializes in producing active pharmaceutical ingredients (APIs), which are essential chemical compounds within medications that facilitate the desired therapeutic effects.
Additionally, Divi’s Labs engages in contract manufacturing of APIs and intermediates for global corporations. A substantial portion of its revenue, exceeding 60%, is generated through exports to the United States and Europe.
In the preceding months, the company disclosed that it faced pricing constraints for certain generic APIs. Several companies, dealing with post-pandemic challenges, struggled to deplete large inventories of generic drug dosages before their expiration dates. Consequently, this surplus supply negatively impacted both prices and demand for generic APIs.
During the quarter, the company also observed a 6.41% increase in the expenses related to materials consumed in its operations.
As of Monday, Divis Labs’ shares concluded trading at Rs.3730.55, marking a 1.40% rise on the NSE (National Stock Exchange).